当前位置:首页 >英文主页 >中英对照 > 报告详情

WCG Clinical:2024临床试验趋势洞见报告(英文版)(36页).pdf

上传人: Kell****reet 编号:157722 2024-03-29 36页 9.46MB

下载:

1、Clinical Trial Trends&Insights 2024Intelligently connecting data and insights to navigate the clinical research trends of tomorrowAdvancing health is all about connections.Connecting people,data,insights,and technology for a better,more efficient clinical trial experience.So as the calendar turns ov

2、er to another year,weve asked our scientific and subject matter experts to connect our data with their expertise and share their thoughts about what trends,changes,and innovations they are looking forward to in 2024 and beyond.While the industry continues to adjust in a post-COVID world,as of this p

3、ublication we expect clinical trial starts in 2024 to be up slightly over 2023.Despite this improvement,disconnects remain.Sites continue to struggle with resourcing and the demands of working in multiple technology platforms.Sites,sponsors,and CROs are working to bridge the gap between artificial i

4、ntelligence,machine learning,drug development,and decision making.All stakeholders are focusing on the continued promise of digital health tools that provide researchers with real-time data,as well as new approaches to clinical trials that prioritize the needs of participants first beyond the protoc

5、ol.In these pages,our experts will connect you with insights to prepare you for what we expect to be another progressive year in the clinical research industry.Foreword2 2024 WCG.All Rights Reserved.Diversity,Equity&Inclusion 4Research Site Readiness 15Decentralized&Hybrid Trials 11EmergingOpportuni

6、ties 26Table of Contents3 2024 WCG.All Rights Reserved.Current Opportunities and Outcomes in Rare Disease Clinical TrialsDiversity,Equity&Inclusion4 2024 WCG.All Rights Reserved.Importance Ratings for Diversityvs.Primary Reasons Diversity wasConsidered to be Important*Racial/EthnicGenderEconomicPati

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要讨论了2024年临床试验趋势和洞察,包括多样性、公平性和包容性(DEI)、研究站点准备情况、去中心化和混合试验以及新兴机会。 1. 多样性、公平性和包容性(DEI)在临床试验中的重要性日益增加,因为缺乏多样性会降低临床试验的质量,增加成本,并可能危及患者安全。 2. 研究站点面临资源配置和多技术平台工作的挑战,各方正在努力弥合人工智能、机器学习、药物开发和决策制定之间的鸿沟。 3. 去中心化和混合试验在疫苗开发中发挥着重要作用,尤其是在COVID-19大流行期间。这些试验允许更以参与者为中心的研究方法,使治疗可以远程提供,赞助商可以与更多样化的患者群体接触,并且可以加速招募工作。 4. 直接向参与者提供试验产品是一个新兴领域,但存在与安全、运输、稳定性、隐私、盲法和合规性相关的重大问题,这阻碍了全面直接向参与者疫苗测试方法的快速采用。
临床试验中的多样性、公平性和包容性有何重要性? 分散式和混合式试验如何影响疫苗研发? 直接面向参与者的疫苗测试方法有哪些挑战?
客服
商务合作
小程序
服务号
折叠